SIK2 and ovarian cancer: In line with this finding, downregulation of SIK2 blocked paclitaxel resistance and attenuated the phenomenon of paclitaxel-resistant ovarian cancer cells, but inhibition of miR-654-5p by inhibitors rescued this inhibitory phenotype (Li et al., 2020a).